For Quick Alerts
For Daily Alerts

Venus Remedies rallies on launch of new cancer formulation


Venus Remedies rallies on launch of new cancer formulation
Shares of Venus Remedies rallied sharply today on reports of the launch of a new cancer drug. The shares of the company were up almost 5% on the National Stock Exchange.

Venus Remedies Limited has introduced for the first time a nanotechnology based "Ready to use" Single Vial Docetaxel in the domestic market under the brand name "TAXEDOLA semi-synthetic cytostatic taxane analogue, Docetaxel is considered as one of the most effective and successful oncology products, which is used mainly for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, head and neck cancer and ovarian cancer.


TAXEDOL (Docetaxel) is a single unit stable, pharmaceutical formulation which has lesser impurities in comparison to innovator product. This one vial formulation of Docetaxel will not only make the administration of the drug easier by introducing the premix solution but at the same time will provide enhanced safety to patients and para-medical staff.

Furthermore, the nano-scale size of the formulation results in improved penetration, higher efficacy, improved safety and lesser side effects.

Read more about: venus remedies
Company Search
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X